Loading…
Employees: 304
Size Jenkem Technology (688356.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $686M, the 3107th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥75.37 on 6 Nov 2026.
Performance Over six months the shares fell 22.6%, against -5.6% for the median peer and -16.4% for the China market (cap-weighted) — 6th lowest of 21 in its peer set.
Growth Revenue grew 51.6% over the last twelve months (peer median +14.1%); the operating margin is 11.5% (peer median 10.7%).
Valuation It trades at 36.8× forward earnings against a peer median of 15.2× (3rd most expensive of 10).
Price implies For today's price to make sense, revenue must grow about 41% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is +30 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 7.5 points below its cost of capital (14.5% WACC).
Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥375M | CN¥313M | CN¥222M | CN¥287M | CN¥403M |
| Revenue growth | — | +41% | -23% | -29% | — |
| Gross profit | CN¥282M | CN¥182M | CN¥135M | CN¥217M | CN¥330M |
| EBITDA | n/a | CN¥104M | CN¥64.5M | CN¥152M | CN¥214M |
| Net income | CN¥50.5M | CN¥61.7M | CN¥29.8M | CN¥116M | CN¥187M |
| Free cash flow | CN¥117M | CN¥30.2M | CN¥99.9M | CN¥49.3M | -CN¥16.1M |
| Capital expenditure | CN¥81.8M | CN¥55.8M | CN¥28.3M | CN¥83.7M | CN¥213M |
| Total debt | CN¥5.56M | CN¥7.12M | CN¥13.6M | CN¥8.81M | CN¥4.64M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688356.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -30.7% | -4.0% | lowest of 21 |
| 6-month return | -22.6% | -5.6% | 6th lowest of 21 |
| Distance from 52-week high | -45.7% | -26.1% | 5th lowest of 21 |
| Revenue growth (TTM) | +51.6% | +14.1% | 4th highest of 17 |
| Operating margin | 11.5% | 10.7% | 8th highest of 16 |
| Forward P/E | 36.8× | 15.2× | 3rd most expensive of 10 |
| Growth the price implies (Req g, 7 yrs) | 41.4% | 10.3% | 2nd most demanding of 10 |
| Growth delivered (Del g) | +11.2% | +7.9% | 3rd highest of 10 |
| Hurdle (Req g minus delivered) | +30.2 pp | +15.6 pp | 3rd most demanding of 10 |
| ROIC minus cost of capital | -7.5 pp | -3.1 pp | 3rd lowest of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Jenkem Technology 688356.SS | China | $686M | -23% | +52% | 11% | 36.8× | 41.4% | +11.2% |
| Shandong Wit Dyne Health 000915.SZ | China | $687M | -33% | -36% | 36% | 9.1× | n/a | n/a |
| Mochida Pharmaceutical 4534.T | Japan | $683M | -6% | +15% | 9% | 15.2× | n/a | n/a |
| Nuvectis Pharma NVCT | United States | $683M | +79% | n/a | n/a | n/a | n/a | n/a |
| Hubei Biocause Heilen Pharmaceutical 301211.SZ | China | $682M | -5% | +13% | 4% | n/a | n/a | n/a |
| Earth 4985.T | Japan | $682M | +6% | +6% | 4% | 17.7× | -2.5% | -1.8% |
| Zevra Therapeutics ZVRA | United States | $690M | +4% | +75% | 31% | 11.8× | 0.0% | +51.6% |
| Achieve Life Sciences ACHV | United States | $692M | +29% | n/a | n/a | n/a | n/a | n/a |
| Beijing Beilu Pharmaceutical 300016.SZ | China | $692M | -16% | +23% | 11% | 88.2× | 10.3% | +7.9% |
| Sagimet Biosciences SGMT | United States | $693M | +28% | n/a | n/a | n/a | n/a | n/a |
| Hunan Fangsheng Pharmaceutical 603998.SS | China | $678M | -6% | +10% | 19% | 12.7× | -2.4% | +6.4% |
| Philogen PHIL.MI | Italy | $694M | -7% | +295% | 79% | 32.5× | n/a | n/a |
| Center Laboratories 4123.TWO | Taiwan | $676M | -28% | +4% | 5% | n/a | 50.8% | +16.2% |
| Bliss GVS Pharma BLISSGVS.NS | India | $698M | +126% | +21% | 15% | n/a | 37.0% | +10.1% |
| FDC FDC.NS | India | $672M | +4% | +10% | 14% | n/a | 25.9% | +10.3% |
| Immix Biopharma IMMX | United States | $668M | -17% | n/a | n/a | n/a | n/a | n/a |
| HeiLongJiang ZBD Pharmaceutical 603567.SS | China | $705M | -29% | -82% | n/a | 6.3× | 10.5% | -25.1% |
| Zhejiang Wecome Pharmaceutical 300878.SZ | China | $666M | +10% | +40% | -65% | n/a | n/a | n/a |
| Sun Pharma Advanced Research SPARC.NS | India | $665M | +16% | +3,141% | 84% | n/a | n/a | n/a |
| Luoxin Pharmaceuticals Group Stock 002793.SZ | China | $664M | -26% | -10% | -9% | n/a | 0.3% | -17.9% |
| Lepu Biopharma 2157.HK | Hong Kong | $663M | -45% | +47% | 7% | 61.2× | n/a | n/a |